204 related articles for article (PubMed ID: 16216496)
1. Pulvinones as bacterial cell wall biosynthesis inhibitors.
Antane S; Caufield CE; Hu W; Keeney D; Labthavikul P; Morris K; Naughton SM; Petersen PJ; Rasmussen BA; Singh G; Yang Y
Bioorg Med Chem Lett; 2006 Jan; 16(1):176-80. PubMed ID: 16216496
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.
Garrison MW; Nuemiller JJ
Int J Antimicrob Agents; 2007 Feb; 29(2):191-6. PubMed ID: 17174074
[TBL] [Abstract][Full Text] [Related]
3. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and antibacterial activity of demethylvancomycin analogues against drug-resistant bacteria.
Chang J; Zhang SJ; Jiang YW; Xu L; Yu JM; Zhou WJ; Sun X
ChemMedChem; 2013 Jun; 8(6):976-84. PubMed ID: 23576378
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the in vitro efficacy of the novel antimicrobial peptide CECT7121 against human Gram-positive bacteria from serious infections refractory to treatment.
Sparo MD; Jones DG; Sánchez Bruni SF
Chemotherapy; 2009; 55(4):270-7. PubMed ID: 19494489
[TBL] [Abstract][Full Text] [Related]
6. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
Huang YT; Liao CH; Teng LJ; Hsueh PR
Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
8. The killing of bacteria by cell wall inhibitors.
Rogers HJ
Contrib Microbiol Immunol; 1973; 1():117-34. PubMed ID: 4805300
[No Abstract] [Full Text] [Related]
9. Potent antibacterial activity of oligo-3-aminopyridine against Staphylococcus aureus and Enterococcus faecalis.
Akgul C; Kaya I
Indian J Biochem Biophys; 2004; 41(2-3):120-2. PubMed ID: 22900341
[TBL] [Abstract][Full Text] [Related]
10. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.
Drago L; Nicola L; De Vecchi E
Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of teichomycin A 2 in comparison with penicillin and vancomycin against gram-positive cocci.
Bauernfeind A; Petermüller C
Eur J Clin Microbiol; 1982 Oct; 1(5):278-81. PubMed ID: 6223812
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial therapy of multidrug-resistant Streptococcus pneumoniae, vancomycin-resistant enterococci, and methicillin-resistant Staphylococcus aureus.
Cunha BA
Med Clin North Am; 2006 Nov; 90(6):1165-82. PubMed ID: 17116442
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of benzenesulfonanilides active against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.
Namba K; Zheng X; Motoshima K; Kobayashi H; Tai A; Takahashi E; Sasaki K; Okamoto K; Kakuta H
Bioorg Med Chem; 2008 Jun; 16(11):6131-44. PubMed ID: 18468909
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
15. Katanosin B and plusbacin A(3), inhibitors of peptidoglycan synthesis in methicillin-resistant Staphylococcus aureus.
Maki H; Miura K; Yamano Y
Antimicrob Agents Chemother; 2001 Jun; 45(6):1823-7. PubMed ID: 11353632
[TBL] [Abstract][Full Text] [Related]
16. The antibacterial action of vancomycin.
Watanakunakorn C
Rev Infect Dis; 1981; 3 suppl():S210-5. PubMed ID: 6805065
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the tolerance of pathogenic enterococci and Staphylococcus aureus to cell wall active antibiotics.
Ladjouzi R; Bizzini A; Lebreton F; Sauvageot N; Rincé A; Benachour A; Hartke A
J Antimicrob Chemother; 2013 Sep; 68(9):2083-91. PubMed ID: 23649229
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus.
Fritsche TR; Rhomberg PR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2008 Apr; 60(4):399-403. PubMed ID: 18178361
[TBL] [Abstract][Full Text] [Related]
19. Triketones active against antibiotic-resistant bacteria: synthesis, structure-activity relationships, and mode of action.
van Klink JW; Larsen L; Perry NB; Weavers RT; Cook GM; Bremer PJ; MacKenzie AD; Kirikae T
Bioorg Med Chem; 2005 Dec; 13(24):6651-62. PubMed ID: 16140015
[TBL] [Abstract][Full Text] [Related]
20. Comparative proteomic analysis of Staphylococcus aureus strains with differences in resistance to the cell wall-targeting antibiotic vancomycin.
Pieper R; Gatlin-Bunai CL; Mongodin EF; Parmar PP; Huang ST; Clark DJ; Fleischmann RD; Gill SR; Peterson SN
Proteomics; 2006 Aug; 6(15):4246-58. PubMed ID: 16826566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
